Alyeska Investment Group L.P. Reduces Stake in enVVeno Medical Corporation (NASDAQ:NVNO)

Alyeska Investment Group L.P. lessened its holdings in shares of enVVeno Medical Corporation (NASDAQ:NVNO - Free Report) by 50.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 209,180 shares of the company's stock after selling 215,820 shares during the quarter. Alyeska Investment Group L.P. owned 1.19% of enVVeno Medical worth $632,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in NVNO. JPMorgan Chase & Co. purchased a new stake in shares of enVVeno Medical during the fourth quarter valued at approximately $816,000. Westside Investment Management Inc. boosted its position in enVVeno Medical by 132.0% during the fourth quarter. Westside Investment Management Inc. now owns 205,025 shares of the company's stock worth $619,000 after purchasing an additional 116,650 shares during the period. Altium Capital Management LLC raised its position in shares of enVVeno Medical by 29.8% in the fourth quarter. Altium Capital Management LLC now owns 310,000 shares of the company's stock valued at $936,000 after purchasing an additional 71,080 shares during the period. Marshall Wace LLP purchased a new stake in shares of enVVeno Medical during the 4th quarter valued at approximately $147,000. Finally, Geode Capital Management LLC boosted its holdings in enVVeno Medical by 20.6% in the 4th quarter. Geode Capital Management LLC now owns 181,737 shares of the company's stock worth $549,000 after buying an additional 31,061 shares during the period. 34.71% of the stock is owned by institutional investors.

enVVeno Medical Trading Up 0.8%

Shares of NVNO stock traded up $0.03 during trading hours on Monday, reaching $3.68. The stock had a trading volume of 45,763 shares, compared to its average volume of 111,870. enVVeno Medical Corporation has a 12 month low of $2.03 and a 12 month high of $6.48. The stock's fifty day simple moving average is $2.78 and its 200 day simple moving average is $3.08. The firm has a market capitalization of $64.53 million, a PE ratio of -2.85 and a beta of 0.80.

enVVeno Medical (NASDAQ:NVNO - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.22) earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that enVVeno Medical Corporation will post -1.32 EPS for the current fiscal year.

enVVeno Medical Company Profile

enVVeno Medical Corporation Nasdaq: NVNO is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).